Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023)
Revolution Medicines (RVMD) posted quarterly EBITDA Margin of 24256.47% for Q4 2023, down 2385394.0% year-over-year from N/an in Q4 2022, and down 752.57% quarter-over-quarter from 2845.11% in Q2 2023.
Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023) Analysis & Trends
Revolution Medicines' EBITDA Margin history runs 5 years deep, the most recent figure standing at 24256.47% for Q4 2023.
- In Q4 2023, EBITDA Margin fell 2385394.0% year-over-year to 24256.47%; the TTM figure through Sep 2024 stood at 88031.94% (down 8662217.0% YoY), while the FY2023 annual figure was 4207.12%, down 347711.0% from the prior year.
- EBITDA Margin for Q4 2023 stood at 24256.47%, down from 2845.11% in the prior quarter.
- The five-year high for EBITDA Margin was 79.26% in Q1 2019, with the low at 24256.47% in Q4 2023.
- The 5-year median for EBITDA Margin is 402.52% (2022), against an average of 2109.23%.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin surged 254813 bps in 2022, then plunged 2385394 bps in 2023.
- Revolution Medicines' EBITDA Margin stood at 161.85% in 2019, then plunged by 141 bps to 389.44% in 2020, then tumbled by 44 bps to 559.33% in 2021, then grew by 28 bps to 402.52% in 2022, then tumbled by 5926 bps to 24256.47% in 2023.
- Business Quant data shows RVMD's EBITDA Margin at 24256.47% in Q4 2023, 2845.11% in Q2 2023, and 1071.53% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -24,256.47% |
| Jun 30, 2023 | -2,845.11% |
| Mar 31, 2023 | -1,071.53% |
| Dec 31, 2022 | -402.52% |
| Sep 30, 2022 | -2,280.48% |
| Jun 30, 2022 | -681.10% |
| Mar 31, 2022 | -764.70% |
| Dec 31, 2021 | -559.33% |
| Sep 30, 2021 | -4,828.61% |
| Jun 30, 2021 | -512.01% |
| Mar 31, 2021 | -369.13% |
| Dec 31, 2020 | -389.44% |
| Sep 30, 2020 | -217.61% |
| Jun 30, 2020 | -279.14% |
| Mar 31, 2020 | -182.59% |
| Dec 31, 2019 | -161.85% |
| Sep 30, 2019 | -108.42% |
| Jun 30, 2019 | -85.99% |
| Mar 31, 2019 | -79.26% |